NeoGenomics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC, disclosing condensed consolidated balance sheet data reflecting changes in assets, liabilities, and stockholders' equity compared to December 31, 2025.

Key Highlights

  • Accumulated deficit: The company reported an accumulated deficit of $456,220 thousand as of September 30, 2026, compared to $433,806 thousand at December 31, 2025.
  • Total assets: Total assets were $1,376,917 thousand as of September 30, 2026, up from $1,359,830 thousand at December 31, 2025.
  • Accounts receivable: Net accounts receivable rose to $213,410 thousand from $159,242 thousand at the prior year-end.
  • Convertible senior notes: Long-term convertible senior notes, net, stood at $374,688 thousand, up from $341,858 thousand at December 31, 2025.
  • Treasury stock: The company held 2,383,222 shares of treasury stock at cost totaling $25,000 thousand; no treasury shares were held at December 31, 2025.
  • Shares outstanding: As of October 23, 2026, the registrant had 129,389,465 shares of common stock outstanding.
  • Total stockholders' equity: Stockholders' equity declined to $800,638 thousand from $836,562 thousand at December 31, 2025.

NeoGenomics Balance Sheet Shifts in the Nine Months Ended September 30, 2026

According to the filing, NeoGenomics, Inc. (NASDAQ:NEO) reported total assets of $1,376,917 thousand as of September 30, 2026, an increase from $1,359,830 thousand at December 31, 2025. The company disclosed that cash and cash equivalents declined to $139,281 thousand from $159,618 thousand at year-end 2025, while net accounts receivable grew by approximately $54,168 thousand over the same period, reaching $213,410 thousand. Inventories decreased to $25,500 thousand from $28,566 thousand.

On the liabilities side, the filing reported that total liabilities rose to $576,279 thousand from $523,268 thousand. Convertible senior notes, net, increased to $374,688 thousand from $341,858 thousand. Total current liabilities grew to $116,173 thousand from $88,300 thousand, driven in part by increases in accounts payable (to $32,925 thousand from $23,090 thousand) and accrued compensation (to $60,477 thousand from $47,580 thousand). The company also disclosed finance lease liabilities of $4,151 thousand long-term and $1,704 thousand current, compared to $27 thousand and $28 thousand, respectively, at December 31, 2025.

The company disclosed that total stockholders' equity fell to $800,638 thousand from $836,562 thousand at the prior year-end, reflecting growth in the accumulated deficit to $456,220 thousand from $433,806 thousand and the addition of $25,000 thousand in treasury stock at cost. Additional paid-in capital increased to $1,281,723 thousand from $1,270,235 thousand. The filing noted that 131,483,771 shares were issued as of September 30, 2026, with 129,100,549 shares outstanding after accounting for 2,383,222 treasury shares. The filing is classified as a large accelerated filer and was filed for the quarterly period ended September 30, 2026.

What Was Disclosed

NeoGenomics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited condensed consolidated balance sheet data, including changes in assets, liabilities, convertible notes, treasury stock activity, and an expanded accumulated deficit relative to December 31, 2025.